+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Global Spinal Muscular Atrophy Market: Industry Analysis & Outlook (2019-2026)

  • ID: 4755690
  • Report
  • Region: Global
  • 72 Pages
  • Koncept Analytics
10% Free customization

This report comes with 10% free customization, enabling you to add data that meets your specific business needs.

1 of 4

FEATURED COMPANIES

  • Biogen Inc.
  • Cytokinetics, Inc
  • Novartis International AG
  • Roche Holding AG
  • MORE

Spinal Muscular Atrophy (SMA) is a form of neuromuscular disease that results in loss of lower motor neurons and progressive muscle wasting, often leading to early death. Presently, it affects about 1 in 11,000 babies and about 1 in every 50 Americans is the disease carrier. On the basis of either the onset age of symptoms, SMA is classified into Type I, Type II, Type III and Type IV diseases.

Currently, no specific therapies for cure exist, but certain speciality drugs are expected to enter the market in the year 2019. The clinical care differs with the severity or type of the disorder category.

The global market is expected to witness a lucrative growth due the rising pharmaceuticals research and development (R&D) expenditures, increasing personal healthcare expenditure, accelerating economic growth and growing spinal muscular atrophy occurrence. The market is trending with progressing drug pipeline and high preference for gene therapy. However, there are some growth hindering factors in the market including lethargic drug approval process and associated business risks.

Regionally, the U.S. is expected to hold the leading position in the market, due to the increasing prevalence of motor neuron disorders in the population along with high preference of genetic correction therapy and myostatin drugs.

“Global Spinal Muscular Atrophy Market: Industry Analysis & Outlook (2019-2026)” by the author provides an extensive research and detailed analysis of the present market along with future outlook. Key players i.e. Biogen Inc., Novartis International AG, Roche Holding AG and Cytokinetics, Inc are being profiled along with their respective financials and growth strategies.


Please note: 10% free customization equates to up to 3 hours of analyst time. Customizations over this would involve an added fee.
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Biogen Inc.
  • Cytokinetics, Inc
  • Novartis International AG
  • Roche Holding AG
  • MORE

1. Market Overview
1.1 Introduction
1.2 Classification
1.3 Causes & Symptoms
1.4 Diagnosis
1.5 Treatment

2. Global Spinal Muscular Atrophy Market
2.1 Global Spinal Muscular Atrophy Market Value Forecast
2.2 Global AVXS-101 Gene Therapy Value Forecast
2.3 Global AVXS-101 Gene Therapy Value Forecast by Region
2.4 Global SRK-015 Drug Value Forecast
2.5 Global SRK-015 Drug Value Forecast by Region
2.6 Global Spinal Muscular Atrophy Incidence by Region
2.7 Global Spinal Muscular Atrophy Prevalence by Region

3. Regional Spinal Muscular Atrophy Market
3.1 The U.S. AVXS-101 Gene Therapy Value Forecast
3.2 The U.S. AVXS-101 Gene Therapy Value Forecast by Disease Type
3.2.1 The U.S. AVXS-101 Gene Therapy Value Forecast by Type I
3.2.2 The U.S. AVXS-101 Gene Therapy Value Forecast by Type II
3.3 The U.S. SRK-015 Drug Value Forecast
3.4 The U.S. SRK-015 Drug Value Forecast by Disease Type
3.4.1 The U.S. SRK-015 Drug Value Forecast by Type I
3.4.2 The U.S. SRK-015 Drug Value Forecast by Type III
3.5 EU AVXS-101 Gene Therapy Value Forecast
3.6 EU AVXS-101 Gene Therapy Value Forecast by Disease Type
3.6.1 EU AVXS-101 Gene Therapy Value Forecast by Type I
3.6.2 EU AVXS-101 Gene Therapy Value Forecast by Type III
3.7 EU SRK-015 Drug Value Forecast
3.8 EU SRK-015 Drug Value Forecast by Disease Type
3.8.1 EU SRK-015 Drug Value Forecast by Type I
3.8.2 EU SRK-015 Drug Value Forecast by Type III

4. Market Dynamics
4.1 Growth Drivers
4.1.1 Rising Pharmaceuticals Research and Development (R&D) Expenditures
4.1.2 Increasing Personal Healthcare Expenditure
4.1.3 Accelerating Economic Growth
4.1.4 Growing Spinal Muscular Atrophy Occurrence
4.2 Key Trends and Developments
4.2.1 Progressing Drug Pipeline
4.2.2 High Preference for Gene Therapy
4.3 Challenges
4.3.1 Lethargic Drug Approval Process
4.3.2 Associated Business Risk

5. Competitive Landscape
5.1 Global Spinal Muscular Atrophy Market
5.1.1 Key Players - Revenue Comparison
5.1.2 Key Players – Drug Features Comparison
5.1.3 Key Players – Market Cap Comparison

6. Company Profiles
6.1 Biogen Inc.
6.1.1 Business Overview
6.1.2 Financial Overview
6.1.3 Business Strategies
6.2 Novartis International AG
6.2.1 Business Overview
6.2.2 Financial Overview
6.2.3 Business Strategies
6.3 Roche Holding AG
6.3.1 Business Overview
6.3.2 Financial Overview
6.3.3 Business Strategies
6.4 Cytokinetics, Inc
6.4.1 Business Overview
6.4.2 Financial Overview
6.4.3 Business Strategies

List of Figures

  • Global Spinal Muscular Atrophy Market Value Forecast (2018-2023)
  • Global AVXS-101 Gene Therapy Market Forecast (2019-2023)
  • Global AVXS-101 Gene Therapy Value Forecast by Region (2019-2023)
  • Global SRK-015 Drug Value Forecast (2022-2026)
  • Global SRK-015 Drug Value Forecast by Region (2022-2026)
  • Global Spinal Muscular Atrophy Incidence by Region (2018)
  • Global Spinal Muscular Atrophy Prevalence by Region (2018)
  • The U.S. AVXS-101 Gene Therapy Value Forecast (2019-2023)
  • The U.S. AVXS-101 Gene Therapy Value Forecast by Disease Type (2019-2023)
  • The U.S. AVXS-101 Gene Therapy Value Forecast by Type I (2019-2023)
  • The U.S. AVXS-101 Gene Therapy Value Forecast by Type II (2020-2024)
  • The U.S. SRK-015 Drug Value Forecast (2022-2026)
  • The U.S. SRK-015 Drug Value Forecast by Disease Type (2022-2026)
  • The U.S. SRK-015 Drug Value Forecast by Type I (2022-2026)
  • The U.S. SRK-015 Drug Value Forecast by Type III (2022-2026)
  • EU AVXS-101 Gene Therapy Value Forecast (2020-2024)
  • EU AVXS-101 Gene Therapy Value Forecast by Disease Type (2020-2024)
  • EU AVXS-101 Gene Therapy Value Forecast by Type I (2020-2024)
  • EU AVXS-101 Gene Therapy Value Forecast by Type III (2021-2025)
  • EU SRK-015 Drug Value Forecast (2023-2027)
  • EU SRK-015 Drug Value Forecast by Disease Type (2023-2027)
  • EU SRK-015 Drug Value Forecast by Type I (2023-2027)
  • EU SRK-015 Drug Value Forecast by Type III (2023-2027)
  • Global Pharmaceuticals Research and Development (R&D) Expenditures (2014-2018)
  • Global HealthCare Expenditure Per Capita (2014-2018)
  • Global Gross Domestic Product (GDP) per Capita (2014-2018)
  • Spinal Muscular Atrophy Drugs Approval Procedure
  • Key Players – Market Cap Comparison (2019)
  • Biogen Revenues by Business Segments (2018)
  • Biogen Revenues and Net Income (2014-2018)
  • Biogen R&D Expenditures (2015-2017)
  • Novartis Net Sales by Business Segments (2018)
  • Novartis Net Sales and Net Income (2014-2018)
  • Roche Sales by Business Segments (2018)
  • Roche Sales and Net Income (2014-2018)
  • Cytokinetics Revenues and Net Income (Loss) (2013-2017)
  • Cytokinetics R&D Expenditures (2015-2017)

List of Tables

  • Spinal Muscular Atrophy Drugs under Development (2018)
  • Key Players - Revenue Comparison (2018)
  • Key Players - Drug Features Comparison (2018)
  • Cytokinetics Product Pipeline (2019)
  • Cytokinetics Partnership Renewal Agreements (2018)
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Biogen Inc.
  • Cytokinetics, Inc
  • Novartis International AG
  • Roche Holding AG
Note: Product cover images may vary from those shown
Adroll
adroll